Investigation of RASSF4 gene in head and neck cancers

ergen, arzu; ATAS, MERVE NUR; ULUSAN, Murat; Aydemir, Levent; karagedik, emine hande; Pamuk, Saim

doi:10.1515/tjb-2021-0026

Investigation of RASSF4 gene in head and neck cancers

emine hande karagedik, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Moleküler Bölümü, İstanbul, Türkiye)

Saim PAMUK, (İstanbul Üniversitesi, Tıp Fakültesi, Bölümü Kulak Burun Boğaz, İstanbul, Türkiye)

Merve Nur ATAŞ, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Moleküler Bölümü, İstanbul, Türkiye)

Murat ULUSAN, (İstanbul Üniversitesi, Tıp Fakültesi, Bölümü Kulak Burun Boğaz, İstanbul, Türkiye)

Levent AYDEMİR, (İstanbul Üniversitesi, Tıp Fakültesi, Bölümü Kulak Burun Boğaz, İstanbul, Türkiye)

HAYRİYE ARZU ERGEN (İstanbul Üniversitesi, Tıp Fakültesi, Bölümü Kulak Burun Boğaz, İstanbul, Türkiye)

Türk Biyokimya Dergisi

7 1

Yıl: 2022 Cilt: 47 Sayı: 1 Sayfa Aralığı: 97 - 101 Metin Dili: İngilizce DOI: 10.1515/tjb-2021-0026 İndeks Tarihi: 17-05-2023

Investigation of RASSF4 gene in head and neck cancers

Öz:

Objectives: RASSF gene family can inhibit the growth of RAS oncogene. This gene family is suggested to have a role in cell cycle control, apoptosis, cell migration, and mitosis control. This study evaluated RASSF4 gene expression levels, SNPs and serum levels in tissues dissected from both healthy individuals and patients diagnosed with head, and neck cancer. Methods: RASSF4 gene expression levels were determined using the RT-PCR. Serumlevels of RASSF4were tested using the Enzyme-Linked Immuno Sorbent Assay technique in study groups. RASSF4 rs7896801 and rs884879 genotypes were identified using by the RT-PCR. Results: No statistical difference was observed between study groups according to RASSF4 gene expression levels. According to SNP results, rs7896801 revealed a 2.4 fold increase of G-allele presence in patients (p=0.015). The increase in the presence of AA genotype was statistically significant for the control group (p=0.015). Distribution of genotypes and alleles for rs884879 showed a 2.2 fold increase in CC genotype for healthy group (p=0.031) however, the presence of T allele showed a significant increase in the patients (p=0.048). Conclusions: We suggest that this study will play a pioneering role for the next studies on RASSF4 gene, especially on SNPs.

Anahtar Kelime:

Baş Boyun Kanserlerinde RASSF4 Geninin Araştırılması

Öz:

Giriş: RASSF ailesi RAS onkogeninin büyümesini engelleyici özellikler gösterir. Bu gen ailesinin hücre döngüsü kontrolü, apoptoz, hücre göçü ve mitoz kontrolünde görev aldıkları tahmin edilmektedir. Amaç: Bu çalışmada RASSF4 gen anlatımı, SNP’ler ve serum düzeyinin baş boyun kanseri hastaları ve sağlıklı bireylerden alınan örneklerde incelenmesi amaçlanmıştır. Materyal Ve Metod: RASSF4 gen anlatımı düzeyleri RT-PCR kullanılarak tayin edilmiştir. Çalışma gruplarında RASSF4 serum düzeyleri ELISA tekniği ile ölçülmüştür. RASSF4 rs7896801 ve rs884879 genotip tayinleri ise RT-PCR kullanılarak gerçekleştirilmiştir. Bulgular: Çalışma grupları arasında RASSF4 gen anlatımları açısından istatistiksel bir farklılık gözlemlenmemiştir. SNP sonuçlarına göre ise rs7896801 G alleli varlığının 2.4 kat hastalarda arttığı gösterilmiştir (p=0.015). Kontrol grubunda ise AA genotip taşıma sıklığı istatistiksel olarak artmıştır (p=0.015). rs884879 için genotip ve allel dağılımına bakıldığında sağlıklı grupta CC genotipi taşımak 2.2 kat artarken (p=0.031), hastalarda ise T alleli görülme sıklığı anlamlı olarak yükselmiştir (p=0.048). Tartışma: Çalışmamız özellikle RASSF4 SNP’leri açısından gelecek çalışmalar için öncü rol oynayacak niteliktedir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Markman M. Head and neck cancer questions& answers | what to ask your doctor | CTCA. https://www.cancercenter.com/cancertypes/ head-and-neck-cancer/questions [Accessed 30 Sep 2020].
2. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Canc 2014;14:395–405.
3. Bruni L, Albero G, Mena M, Gomez D, Munoz J, Bosch FX, et al, ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. In: Summary Report. Barcelona, Spain: HPV Information Centre; 2019.
4. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49–54.
5. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999–9006.
6. Hueber AO, Evan GI. Traps to catch unwary oncogenes. Trends Genet 1998;14:364–7.
7. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4/ AD037 is a potential Ras effector/tumor suppressor of the RASSF family. Canc Res 2004;64:8688–93.
8. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumoursuppressor gene cluster. Oncogene 2007;26:7283–301.
9. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Canc Res 2000;60:6116–33.
10. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315–9.
11. Sherwood V, Recino A, Jeffries A, Ward A, Chalmers AD. The N-terminal RASSF family: a new group of Ras-associationdomaincontaining proteins, with emerging links to cancer formation. Biochem J 2010;425:303–11.
12. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009;1796:114–28.
13. Scheel H, Hofmann K. A novel inter action motif, SARAH, connects three classes of tumor suppressor. Curr Biol 2003;13:899–900.
14. Han Y, Dong Q, Hao J, Fu L, Han X, Zheng X, et al. RASSF4 is downregulated in nonsmall cell lung cancer and inhibits cancer cell proliferation and invasion. Tumour Biol 2016;37:4865–71.
15. Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX, Shao JY. Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther 2014;7:457–67.
16. Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle 2006;5:1607–11.
17. Ma BB, Lui VW, Poon FF, Wong SCC, To KF, Wong E, et al. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest N Drugs 2010;28:326–33.
18. Hui ABY, Lo KW, Teo PML, To KF, Huang DP. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol 2002;20:467–73.
19. Chow LSN, Lo KW, Kwong J, Wong AYH, Huang DP. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 2004;12:781–7.
20. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 2009;22: 1519–26.
21. Zhang M, Wang D, Zhu T, Yin R. RASSF4 overexpression inhibits the proliferation, invasion, EMT, and Wnt signaling pathway in osteosarcoma cells. Oncol Res 2017;25:83–91.
22. Porter MJ, Field JK, Leung SF, Lo D, Lee JC, Spandidos DA, et al. The detection of the c-myc and ras oncogenes in nasopharyngeal carcinoma by immunohistochemistry. Acta Otolaryngol 1994;114: 105–9.
23. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349: 2042–54.
24. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Canc Res 2004; 64:1975–86.
25. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Canc Res 2004;64:1664–8.
26. Lehmann U, Länger F, Feist H, Glöckner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605–12.
27. Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Ishizuka T, Saito R, et al. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int J Oncol 2007;31:169–73.
28. EndohM, TamuraG, Honda T,HommaN, TerashimaM,Nishizuka S, et al. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Canc 2005;93:1395–9.
29. Vos MD, Ellis CA, Elam C, Ülkü AS, Taylor BJ, Clark GJ, et al. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003;278:28045–51.
30. De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, et al. Loss of RASSF4 expression in multiple myeloma promotes RAS-driven malignant progression. Canc Res 2018;78:1155–68.

APA	karagedik e, Pamuk S, ATAS M, ULUSAN M, Aydemir L, ergen a (2022). Investigation of RASSF4 gene in head and neck cancers. , 97 - 101. 10.1515/tjb-2021-0026
Chicago	karagedik emine hande,Pamuk Saim,ATAS MERVE NUR,ULUSAN Murat,Aydemir Levent,ergen arzu Investigation of RASSF4 gene in head and neck cancers. (2022): 97 - 101. 10.1515/tjb-2021-0026
MLA	karagedik emine hande,Pamuk Saim,ATAS MERVE NUR,ULUSAN Murat,Aydemir Levent,ergen arzu Investigation of RASSF4 gene in head and neck cancers. , 2022, ss.97 - 101. 10.1515/tjb-2021-0026
AMA	karagedik e,Pamuk S,ATAS M,ULUSAN M,Aydemir L,ergen a Investigation of RASSF4 gene in head and neck cancers. . 2022; 97 - 101. 10.1515/tjb-2021-0026
Vancouver	karagedik e,Pamuk S,ATAS M,ULUSAN M,Aydemir L,ergen a Investigation of RASSF4 gene in head and neck cancers. . 2022; 97 - 101. 10.1515/tjb-2021-0026
IEEE	karagedik e,Pamuk S,ATAS M,ULUSAN M,Aydemir L,ergen a "Investigation of RASSF4 gene in head and neck cancers." , ss.97 - 101, 2022. 10.1515/tjb-2021-0026
ISNAD	karagedik, emine hande vd. "Investigation of RASSF4 gene in head and neck cancers". (2022), 97-101. https://doi.org/10.1515/tjb-2021-0026

APA	karagedik e, Pamuk S, ATAS M, ULUSAN M, Aydemir L, ergen a (2022). Investigation of RASSF4 gene in head and neck cancers. Türk Biyokimya Dergisi, 47(1), 97 - 101. 10.1515/tjb-2021-0026
Chicago	karagedik emine hande,Pamuk Saim,ATAS MERVE NUR,ULUSAN Murat,Aydemir Levent,ergen arzu Investigation of RASSF4 gene in head and neck cancers. Türk Biyokimya Dergisi 47, no.1 (2022): 97 - 101. 10.1515/tjb-2021-0026
MLA	karagedik emine hande,Pamuk Saim,ATAS MERVE NUR,ULUSAN Murat,Aydemir Levent,ergen arzu Investigation of RASSF4 gene in head and neck cancers. Türk Biyokimya Dergisi, vol.47, no.1, 2022, ss.97 - 101. 10.1515/tjb-2021-0026
AMA	karagedik e,Pamuk S,ATAS M,ULUSAN M,Aydemir L,ergen a Investigation of RASSF4 gene in head and neck cancers. Türk Biyokimya Dergisi. 2022; 47(1): 97 - 101. 10.1515/tjb-2021-0026
Vancouver	karagedik e,Pamuk S,ATAS M,ULUSAN M,Aydemir L,ergen a Investigation of RASSF4 gene in head and neck cancers. Türk Biyokimya Dergisi. 2022; 47(1): 97 - 101. 10.1515/tjb-2021-0026
IEEE	karagedik e,Pamuk S,ATAS M,ULUSAN M,Aydemir L,ergen a "Investigation of RASSF4 gene in head and neck cancers." Türk Biyokimya Dergisi, 47, ss.97 - 101, 2022. 10.1515/tjb-2021-0026
ISNAD	karagedik, emine hande vd. "Investigation of RASSF4 gene in head and neck cancers". Türk Biyokimya Dergisi 47/1 (2022), 97-101. https://doi.org/10.1515/tjb-2021-0026